Skip to main content
Premium Trial:

Request an Annual Quote

CardioDX Deploys Revolution's R-Based Software for Cardiovascular Test Development


The article has been updated to provide additional information about Revolution Analytics.

This week, Revolution Analytics said that CardioDX, a diagnostic developer focused on cardiovascular disease, has implemented its Revolution R Enterprise software.

The software is built on the open source R statistics language and incorporates all of its capabilities in addition to commercial enhancements that aren’t available in the free model, such as specialized performance enhancements, visual development tools that help R programmers write and debug R code faster, and the ability to analyze terabyte-sized datasets, among other features.

Revolution said that CardioDX used the software to develop an algorithm for use in its Corus CAD test, which measures the expression of 23 genes in blood samples to identify patients at risk for coronary artery disease.

Michael Elashoff, director of biostatistics at CardioDX, said that Revolution R "offers even greater speed than open source R and allowed us to run analyses for the Corus CAD faster than we could with any alternative." He added that his team relies on R "for nearly all of our research projects."

Revolution Analytics, formerly called Revolution Computing, was founded in 2007 to address the needs of commercial users of the R programming language. The company was relaunched under its new name in May 2010 and moved its headquarters to Palo Alto, Calif.

Founded in 2004, CardioDX is a privately held cardiovascular genomic diagnostics company that provides tests for diseases such as coronary artery disease, cardiac arrhythmias, and heart failure.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.